Antigenics Will Collect Survival Data Before Taking Next Steps With Oncophage Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Antigenics will work with FDA to determine an appropriate path to market for the kidney cancer vaccine, but the firm says it would need a partner if another trial is needed.
You may also be interested in...
Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study
Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.
Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study
Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.
Genitope Maintains Positive View On MyVax Despite DSMB Interim Review
Data safety monitoring board recommends Genitope continue a Phase III trial of the cancer vaccine, suggesting more data is needed.